Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive and increasingly recognized cause of heart failure which is associated with high mortality and morbidity. ATTR-CM is characterized by the misfolding of TTR monomers and their deposition within the myocardium as amyloid fibrils. Th...
Main Authors: | Paolo Morfino, Alberto Aimo, Giuseppe Vergaro, Chiara Sanguinetti, Vincenzo Castiglione, Maria Franzini, Marco Alfonso Perrone, Michele Emdin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/4/1129 |
Similar Items
-
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
by: Daniela Tomasoni, et al.
Published: (2023-05-01) -
SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01) -
Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
by: Maximilian Leo Müller, et al.
Published: (2024-07-01) -
Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
by: Falcão de Campos C, et al.
Published: (2023-02-01) -
Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients)
by: Thibaud Damy, et al.
Published: (2024-01-01)